Silk as an innovative biomaterial for cancer therapy

Reports of Practical Oncology and Radiotherapy

Volumn 20, Issue 2, 2015, Pages 87-98

  Jastrzebska, Katarzyna ^a,b   Kucharczyk, Kamil ^a   Florczak, Anna ^a,b   Dondajewska, Ewelina ^a   Mackiewicz, Andrzej ^a,c,d   Dams Kozlowska, Hanna ^a,c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b ADAM MICKIEWICZ UNIVERSITY   (Poland)

^c GREATER POLAND CANCER CENTRE   (Poland)

^d BioContract   (Poland)

Author keywords

3D cancer model; Bioengineered silk; Cancer therapy; Drug delivery; Silkworm silk; Spider silk

Indexed keywords

ANTINEOPLASTIC AGENT; BIOMATERIAL; DRUG CARRIER; NANOSPHERE; SCAFFOLD PROTEIN; SILK; SILK FIBROIN;

BINDING SITE; BIOCOMPATIBILITY; BIODEGRADABILITY; BIOENGINEERING; BOMBYX MORI; CANCER MODEL; CANCER RESEARCH; CANCER THERAPY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; GENETIC ENGINEERING; HUMAN; IMMUNOGENICITY; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOLOGY; REVIEW; SERICULTURE; SPIDER; TISSUE ENGINEERING; TISSUE SCAFFOLD; TUMOR MICROENVIRONMENT;

EID: 84924004081     PISSN: 15071367     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rpor.2014.11.010     Document Type: Review

References (71)

1. Vepari C., Kaplan D.L. Silk as a biomaterial. Prog Polym Sci 2007, 32:991-1007.
2. Omenetto F.G., Kaplan D.L. New opportunities for an ancient material. Science 2010, 329:528-531.
3. Kundu B., Rajkhowa R., Kundu S.C., Wang X. Silk fibroin biomaterials for tissue regenerations. Adv Drug Deliv Rev 2013, 65:457-470.
4. Kazmierska K., Florczak A., Piekos K., Mackiewicz A., Dams-Kozlowska H. Engineered spider silk: the intelligent biomaterial of the future, Part II. Postepy Hig Med Dosw 2011, 65:389-396. [online].
5. Schacht K., Scheibel T. Processing of recombinant spider silk proteins into tailor-made materials for biomaterials applications. Curr Opin Biotechnol 2014, 29C:62-69.
6. Heim M., Keerl D., Scheibel T. Spider silk: from soluble protein to extraordinary fiber. Angew Chem Int Ed Engl 2009, 48:3584-3596.
7. Spiess K., Lammel A., Scheibel T. Recombinant spider silk proteins for applications in biomaterials. Macromol Biosci 2010, 10:998-1007.
8. Slotta U., Hess S., Spiess K., Stromer T., Serpell L., Scheibel T. Spider silk and amyloid fibrils: a structural comparison. Macromol Biosci 2007, 7:183-188.
9. Hagn F., Eisoldt L., Hardy J.G., et al. A conserved spider silk domain acts as a molecular switch that controls fibre assembly. Nature 2010, 465:239-242.
10. Eisoldt L., Thamm C., Scheibel T. Review the role of terminal domains during storage and assembly of spider silk proteins. Biopolymers 2012, 97:355-361.
11. Scheibel T. Spider silks: recombinant synthesis, assembly, spinning, and engineering of synthetic proteins. Microb Cell Fact 2004, 3:14.
12. Vendrely C., Scheibel T. Biotechnological production of spider-silk proteins enables new applications. Macromol Biosci 2007, 7:401-409.
13. Tokareva O., Jacobsen M., Buehler M., Wong J., Kaplan D.L. Structure-function-property-design interplay in biopolymers: spider silk. Acta Biomater 2014, 10:1612-1626.
14. Florczak A., Piekos K., Kazmierska K., Mackiewicz A., Dams-Kozlowska H. Engineered spider silk: the intelligent biomaterial of the future, Part I. Postepy Hig Med Dosw 2011, 65:377-388. [online].
15. Seib F.P., Kaplan D.L. Doxorubicin-loaded silk films: drug-silk interactions and in vivo performance in human orthotopic breast cancer. Biomaterials 2012, 33:8442-8450.
16. Seib F.P., Pritchard E.M., Kaplan D.L. Self-assembling doxorubicin silk hydrogels for the focal treatment of primary breast cancer. Adv Funct Mater 2013, 23:58-65.
17. Cheema S.K., Gobin A.S., Rhea R., Lopez-Berestein G., Newman R.A., Mathur A.B. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. Int J Pharm 2007, 341:221-229.
18. Seib F.P., Jones G.T., Rnjak-Kovacina J., Lin Y., Kaplan D.L. pH-dependent anticancer drug release from silk nanoparticles. Adv Healthc Mater 2013, 2:1606-1611.
19. Mathur A.B., Gupta V. Silk fibroin-derived nanoparticles for biomedical applications. Nanomedicine (Lond) 2010, 5:807-820.
20. Wu P., Liu Q., Li R., et al. Facile preparation of paclitaxel loaded silk fibroin nanoparticles for enhanced antitumor efficacy by locoregional drug delivery. ACS Appl Mater Interfaces 2013, 5:12638-12645.
21. Subia B., Kundu S.C. Drug loading and release on tumor cells using silk fibroin-albumin nanoparticles as carriers. Nanotechnology 2013, 24:035103.
22. Gupta V., Aseh A., Rios C.N., Aggarwal B.B., Mathur A.B. Fabrication and characterization of silk fibroin-derived curcumin nanoparticles for cancer therapy. Int J Nanomed 2009, 4:115-122.
23. Lammel A.S., Hu X., Park S.H., Kaplan D.L., Scheibel T.R. Controlling silk fibroin particle features for drug delivery. Biomaterials 2010, 31:4583-4591.
24. Chiu B., Coburn J., Pilichowska M., et al. Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model. Br J Cancer 2014, 111:708-715.
25. Yucel T., Lovett M.L., Giangregorio R., Coonahan E., Kaplan D.L. Silk fibroin rods for sustained delivery of breast cancer therapeutics. Biomaterials 2014, 35:8613-8620.
26. Guziewicz N.A., Massetti A.J., Perez-Ramirez B.J., Kaplan D.L. Mechanisms of monoclonal antibody stabilization and release from silk biomaterials. Biomaterials 2013, 34:7766-7775.
27. Guziewicz N., Best A., Perez-Ramirez B., Kaplan D.L. Lyophilized silk fibroin hydrogels for the sustained local delivery of therapeutic monoclonal antibodies. Biomaterials 2011, 32:2642-2650.
28. Chen M., Shao Z., Chen X. Paclitaxel-loaded silk fibroin nanospheres. J Biomed Mater Res A 2012, 100:203-210.
29. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010, 624:25-37.
30. Gobin A.S., Rhea R., Newman R.A., Mathur A.B. Silk-fibroin-coated liposomes for long-term and targeted drug delivery. Int J Nanomed 2006, 1:81-87.
31. Megeed Z., Cappello J., Ghandehari H. Genetically engineered silk-elastinlike protein polymers for controlled drug delivery. Adv Drug Deliv Rev 2002, 54:1075-1091.
32. Greish K., Araki K., Li D., et al. Silk-elastinlike protein polymer hydrogels for localized adenoviral gene therapy of head and neck tumors. Biomacromolecules 2009, 10:2183-2188.
33. Gustafson J., Greish K., Frandsen J., Cappello J., Ghandehari H. Silk-elastinlike recombinant polymers for gene therapy of head and neck cancer: from molecular definition to controlled gene expression. J Control Release 2009, 140:256-261.
34. Xia X.X., Wang M., Lin Y., Xu Q., Kaplan D.L. Hydrophobic drug-triggered self-assembly of nanoparticles from silk-elastin-like protein polymers for drug delivery. Biomacromolecules 2014, 15:908-914.
35. Blüm C., Scheibel T. Control of drug loading and release properties of spider silk sub-microparticles. BioNanoScience 2012, 2:67-74.
36. Lammel A., Schwab M., Hofer M., Winter G., Scheibel T. Recombinant spider silk particles as drug delivery vehicles. Biomaterials 2011, 32:2233-2240.
37. Hofer M., Winter G., Myschik J. Recombinant spider silk particles for controlled delivery of protein drugs. Biomaterials 2011, 33:1554-1562.
38. Numata K., Mieszawska-Czajkowska A.J., Kvenvold L.A., Kaplan D.L. Silk-based nanocomplexes with tumor-homing peptides for tumor-specific gene delivery. Macromol Biosci 2012, 12:75-82.
39. Numata K., Reagan M.R., Goldstein R.H., Rosenblatt M., Kaplan D.L. Spider silk-based gene carriers for tumor cell-specific delivery. Bioconjug Chem 2011, 22:1605-1610.
40. Florczak A., Mackiewicz A., Dams-Kozlowska H. Functionalized spider silk spheres as drug carriers for targeted cancer therapy. Biomacromolecules 2014, 15:2971-2981.
41. Huemmerich D., Helsen C.W., Quedzuweit S., Oschmann J., Rudolph R., Scheibel T. Primary structure elements of spider dragline silks and their contribution to protein solubility. Biochemistry 2004, 43:13604-13612.
42. Slotta U.K., Rammensee S., Gorb S., Scheibel T. An engineered spider silk protein forms microspheres. Angew Chem Int Ed Engl 2008, 47:4592-4594.
43. Lammel A., Schwab M., Slotta U., Winter G., Scheibel T. Processing conditions for the formation of spider silk microspheres. ChemSusChem 2008, 1:413-416.
44. Liebmann B., Hummerich D., Scheibel T., Fehr M. Formulation of poorly water-soluble substances using self-assembling spider silk protein. Colloids Surf A 2008, 331:126-132.
45. Hermanson K.D., Harasim M.B., Scheibel T., Bausch A.R. Permeability of silk microcapsules made by the interfacial adsorption of protein. Phys Chem Chem Phys 2007, 9:6442-6446.
46. Hermanson K., Huemmerich D., Scheibel T., Bausch A. Engineered microcapsules fabricated from reconstituted spider silk. Adv Mater 2007, 19:1810-1815.
47. Blüm C., Nichtl A., Scheibel T. Spider silk capsules as protective reaction containers for enzymes. Adv Funct Mater 2014, 23:763-768.
48. Christian S., Pilch J., Akerman M.E., Porkka K., Laakkonen P., Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003, 163:871-878.
49. Hu Q., Gao X., Kang T., et al. CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels. Biomaterials 2013, 34:9496-9508.
50. Witton C.J., Reeves J.R., Going J.J., Cooke T.G., Bartlett J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200:290-297.
51. Spiess K., Wohlrab S., Scheibel T. Structural characterization and functionalization of engineered spider silk films. Soft Matter 2010, 6:4168-4174.
52. Jansson R., Thatikonda N., Lindberg D., et al. Recombinant spider silk genetically functionalized with affinity domains. Biomacromolecules 2014, 15:1696-1706.
53. Wohlrab S., Muller S., Schmidt A., et al. Cell adhesion and proliferation on RGD-modified recombinant spider silk proteins. Biomaterials 2012, 33:6650-6659.
54. Bini E., Foo C.W., Huang J., Karageorgiou V., Kitchel B., Kaplan D.L. RGD-functionalized bioengineered spider dragline silk biomaterial. Biomacromolecules 2006, 7:3139-3145.
55. Baoyong L., Jian Z., Denglong C., Min L. Evaluation of a new type of wound dressing made from recombinant spider silk protein using rat models. Burns 2010, 36:891-896.
56. Widhe M., Johansson U., Hillerdahl C.O., Hedhammar M. Recombinant spider silk with cell binding motifs for specific adherence of cells. Biomaterials 2013, 34:8223-8234.
57. Wang C., Tang Z., Zhao Y., Yao R., Li L., Sun W. Three-dimensional in vitro cancer models: a short review. Biofabrication 2014, 6:022001.
58. Xu X., Farach-Carson M.C., Jia X. Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol Adv 2014, 32:1256-1268.
59. Tan P.H., Aung K.Z., Toh S.L., Goh J.C., Nathan S.S. Three-dimensional porous silk tumor constructs in the approximation of in vivo osteosarcoma physiology. Biomaterials 2011, 32:6131-6137.
60. Talukdar S., Mandal M., Hutmacher D.W., Russell P.J., Soekmadji C., Kundu S.C. Engineered silk fibroin protein 3D matrices for in vitro tumor model. Biomaterials 2011, 32:2149-2159.
61. Bulysheva A.A., Bowlin G.L., Petrova S.P., Yeudall W.A. Enhanced chemoresistance of squamous carcinoma cells grown in 3D cryogenic electrospun scaffolds. Biomed Mater 2013, 8:055009.
62. Kundu B., Saha P., Datta K., Kundu S.C. A silk fibroin based hepatocarcinoma model and the assessment of the drug response in hyaluronan-binding protein 1 overexpressed HepG2 cells. Biomaterials 2013, 34:9462-9474.
63. Moreau J.E., Anderson K., Mauney J.R., Nguyen T., Kaplan D.L., Rosenblatt M. Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Res 2007, 67:10304-10308.
64. Mbeunkui F., Johann D.J. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 2009, 63:571-582.
65. Reagan M.R., Seib F.P., McMillin D.W., et al. Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ. J Breast Cancer 2012, 15:273-282.
66. Dams-Kozlowska H., Majer A., Tomasiewicz P., Lozinska J., Kaplan D.L., Mackiewicz A. Purification and cytotoxicity of tag-free bioengineered spider silk proteins. J Biomed Mater Res A 2013, 101:456-464.
67. Rabotyagova O.S., Cebe P., Kaplan D.L. Self-assembly of genetically engineered spider silk block copolymers. Biomacromolecules 2009, 10:229-236.
68. Rammensee S., Slotta U., Scheibel T., Bausch A.R. Assembly mechanism of recombinant spider silk proteins. Proc Natl Acad Sci U S A 2008, 105:6590-6595.
69. Heim M., Ackerschott C.B., Scheibel T. Characterization of recombinantly produced spider flagelliform silk domains. J Struct Biol 2010, 170:420-425.
70. Hedhammar M., Rising A., Grip S., et al. Structural properties of recombinant nonrepetitive and repetitive parts of major ampullate spidroin 1 from Euprosthenops australis: implications for fiber formation. Biochemistry 2008, 47:3407-3417.
71. Xia X.X., Xu Q., Hu X., Qin G., Kaplan D.L. Tunable self-assembly of genetically engineered silk-elastin-like protein polymers. Biomacromolecules 2011, 12:3844-3850.